The present disclosure relates to improved oral immunotherapy methods for treating peanut allergy. The disclosure provides methods for treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase. In certain embodiments, the methods comprise non-daily administration to the subject of a maintenance phase dose. In certain embodiments, the methods comprise administering a maintenance phase dose for more than 24 weeks. In other embodiments, the disclosure provides methods for reducing the risk of an allergic adverse event in a subject receiving an oral immunotherapy dosage therapy.
